Vimarsana
Biggest News Aggregation in the World

Douglasv Faller News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Douglasv Faller. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Douglasv Faller Today - Breaking & Trending Today

ORYZON Announces Topline Results from Phase IIb PORTICO - Vimarsana News

ORYZON Announces Topline Results from Phase IIb PORTICO

Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT. An executive summary of the data to be presented at the 7th...

ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD) - Vimarsana News

ORYZON Announces Topline Results from Phase IIb PORTICO Study of Vafidemstat in Borderline Personality Disorder (BPD)

Company to host Conference Call and live Webcast on Sunday, January 7, 2024 at 5:30 pm PT.An executive summary of the data to be presented at the ...

ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b adaptive trial in Borderline Personality Disorder - Vimarsana News

ORYZON announces positive results from planned interim analysis of PORTICO, a Phase 2b adaptive trial in Borderline Personality Disorder

Based on interim efficacy and safety data, Independent Data Monitoring Committee recommends continuation of the trial

Source: asebio.com
ORYZON Reports Results and Corporate Update for Quarter - Vimarsana News

ORYZON Reports Results and Corporate Update for Quarter

Oryzon invests $4.2 million in R&D in the first quarter 2022...

ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2022 - Vimarsana News

ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2022

05.05.2022 - Oryzon invests $4.2 million in R&D in the first quarter 2022MADRID, Spain and CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) - Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics ...